Disease · MONDO_0002113

peritoneal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. peritoneal carcinoma. Diseases, record MONDO_0002113. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002113

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: peritoneal carcinoma; Open Targets
Open Targets ID: MONDO_0002113; Open Targets
Other names: carcinoma of peritoneum, peritoneum carcinoma; Open Targets
Disease Ontology: DOID:1791; Disease Ontology
Highest stage of its drugs: Phase 3, for 7 of its 18 drugs, from ClinicalTrials.gov; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
OREGOVOMAB	CHEMBL2107917	Antibody	Phase 3	ClinicalTrials.gov	4	4	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TOPOTECAN	CHEMBL84	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets51

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor antagonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2260	Drugs and targets

1 to 10 of 51

See all 51 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00316173	Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer	Phase 2	77	2009-11-26	Ovarian Cancer, Neoplasms, Ovarian	CARBOPLATIN, TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT00407563	Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer	Phase 2	48	2012-04-05	Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma	BEVACIZUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00768144	Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma	Phase 2	36	2014-12-02	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02834975	Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).	Phase 2	26	2023-11-07	Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer	CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00511992	Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer	Phase 2	20	2017-07-02	Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma	BEVACIZUMAB, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01936974	(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma	Phase 2	7	2017-10-25	Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma	BEVACIZUMAB, CARBOPLATIN, CISPLATIN, GEMCITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00003636	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer	Phase 3	704		Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer	CARBOPLATIN, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01837251	Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer	Phase 3	682		Recurrent Platinum-sensitive Ovarian Cancer	BEVACIZUMAB, CARBOPLATIN, DOXORUBICIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT04498117	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	Phase 3	615		Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT05080946	Using Aspirin to Improve Immunological Features of Ovarian Tumors	Early phase 1	100		Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	ASPIRIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Dose-finding Phase vs Activity Assessment Phase: serious adverse events	6 of 22	12 of 55	77	NCT00316173

Source Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32305099	RESULT	1	PubMed
31916979	RESULT	1	PubMed
31897661	RESULT	1	PubMed
20850296	RESULT	1	PubMed
20818904	RESULT	1	PubMed
17918264	RESULT	1	PubMed
16959305	RESULT	1	PubMed
37000264	DERIVED	1	PubMed
29324537	DERIVED	1	PubMed
25964591	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002113

GET https://conductscience.org/api/diseases/v1/MONDO_0002113/targets?page=2

API reference For AI assistants